Sarl Cpcm Pharmaceutical Import Profile — Algeria (DGFT 2022–2026)

Name: Sarl Cpcm Pharmaceutical Import Records from India — 2 Products, $400.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sarl Cpcm — Pharmaceutical Importer Profile (2026) | 2 Products, $400.0K Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Sarl Cpcm?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Zydus Lifesciences Limited	$213.0K	6	74.9%
Medopharm	$71.3K	2	25.1%

Sarl Cpcm sources from 2 verified Indian suppliers across 7 distinct formulations. Total import value: $284.2K across 8 shipments.

What Formulations Does Sarl Cpcm Import?

Formulation	Value	Ships
Hydroxychloroquine sulphate 200 MG granules hydroxychloroquine sulfate b nog300160 mfg dt 01 2023 exp dt 12	$100.0K	2
Prednisolone direct compresion	$50.0K	1
Hydroxychloroquine sulphate 200 MG	$50.0K	1
Hydroxychloroquine sulphate 200 MG granules (hydroxychloroquine sulfate tabs usp200mg)	$50.0K	1
Digoxin tablets BP 0.25MG	$21.3K	1
Paraxotine 20MG granules paroxetine b no g203120 mfg dt 11 2022 exp dt 10	$6.5K	1
Paroxetine 20MG granules (paroxetine)

What Products Does Sarl Cpcm Import?

Top Products by Import Value

1Chloroquine$200.0K 2Hydroxychloroquine$200.0K

Sarl Cpcm Therapeutic Categories — 1 Specializations

Sarl Cpcm imports across 1 therapeutic categories, with Antimalarial & Antiparasitic (100.0%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Antimalarial & Antiparasitic

2 products · 100.0% · $400.0K

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Chloroquine	Antimalarial & Antiparasitic	$200.0K	4	0.1%	13
2	Hydroxychloroquine	Antimalarial & Antiparasitic	$200.0K	4	0.1%	9

Key Metrics

Total Import Value$400.0K

Products2

Shipments8

Categories1

CountryAlgeria

#1 Rankings0

Indian Suppliers2

Formulations7

Top Categories

Antimalarial & Antiparasitic100.0%

Indian Suppliers

Last updated: March 28, 2026

Sarl Cpcm — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Sarl Chimie Pharmacie Commerce Multiple (CPCM) is a private limited liability company based in Bordj El Bahri, Wilaya d'Alger, Algeria. Established on August 5, 1997, with a capital of 462 million Algerian Dinars, CPCM specializes in the pharmaceutical industry, focusing on the manufacturing of pharmaceutical products. The company operates as a pharmaceutical importer and buyer, playing a significant role in Algeria's pharmaceutical distribution network by sourcing and supplying essential medicines to meet local demand.

2Distribution Network

CPCM's distribution network is centered in Bordj El Bahri, a suburb of Algiers, which serves as its primary operational hub. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in the capital region suggests a focus on efficient distribution within Algeria. The extent of its geographic coverage beyond Bordj El Bahri is not specified, indicating that CPCM's operations may be primarily concentrated within the national market.

3Industry Role

Supplier Relationship Intelligence — Sarl Cpcm

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

CPCM's sourcing strategy exhibits a high degree of concentration, with a total import value of $400,000 USD from India over eight shipments, all comprising two products: Chloroquine and Hydroxychloroquine. This indicates a reliance on a limited number of products and suppliers, which could pose risks such as supply chain disruptions or regulatory changes affecting these specific medicines. The shipment data reveals that CPCM has engaged with two Indian suppliers: Zydus Lifesciences Limited, accounting for 74.9% of the shipments, and Medopharm, comprising 25.1%. This suggests a stable relationship with these suppliers, though the lack of diversification in product offerings may limit CPCM's ability to adapt to changing market demands or regulatory environments.

2Supply Chain Resilience

CPCM's supply chain resilience appears limited due to its concentrated sourcing strategy. The company's dependence on two suppliers for a narrow range of products may expose it to risks associated with supply chain disruptions, such as production delays, quality issues, or geopolitical factors affecting trade routes. The absence of backup suppliers and limited formulation diversity further exacerbate this vulnerability. Additionally, the specific shipping routes and regulatory compliance statuses of the key suppliers are not detailed, making it challenging to assess the full extent of potential risks.

3Strategic Implications

CPCM's concentrated sourcing pattern may impact its competitive position by limiting its ability to offer a diverse product portfolio and respond flexibly to market changes. For Indian exporters, this presents an opportunity to introduce a broader range of pharmaceutical products to CPCM, potentially reducing the company's supply chain risks and enhancing its market competitiveness. Diversifying CPCM's supplier base and product offerings could lead to more robust partnerships and improved market positioning.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Algeria — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Algeria

1Regulatory Authority & Framework

The Ministry of the Pharmaceutical Industry is the primary regulatory authority overseeing pharmaceutical imports in Algeria. Key legislation governing these imports includes Decree No. 24, issued on October 1, 2025, which outlines the requirements, procedures, and compliance obligations for licensing pharmaceutical import establishments. This decree modernizes the application process and strengthens oversight of pharmaceutical import activities, replacing the previous decree from December 20, 2021. The National Agency for Pharmaceutical Products (ANPP) is responsible for drug registration and medical device approval, ensuring that imported products meet national standards. (miph.gov.dz)

2Import Licensing & GMP

Import licensing requirements in Algeria are governed by Decree No. 24, which stipulates that pharmaceutical import establishments must obtain authorization from the Ministry of the Pharmaceutical Industry. This process involves submitting an application file containing specific documents, undergoing inspections, and adhering to compliance obligations. The decree also defines the procedures for substantial modifications, renewal, and withdrawal of authorizations. Regarding Good Manufacturing Practice (GMP) certification, Algeria recognizes standards such as EU GMP, WHO GMP, and PIC/S. Importers must ensure that their suppliers hold valid GMP certificates from recognized authorities to comply with Algerian regulations.

3Quality & Labeling

Imported pharmaceutical products must undergo batch testing and meet stability requirements as per Algerian regulations. Labeling must be in Arabic and French, providing essential information such as product name, dosage form, strength, manufacturing details, and expiration date. Serialization mandates may apply to ensure traceability and prevent counterfeit products from entering the market. Importers are responsible for ensuring that their products comply with these quality and labeling standards to facilitate smooth customs clearance and market acceptance.

4Recent Regulatory Changes

In October 2025, Algeria's Ministry of the Pharmaceutical Industry issued Decree No. 24, establishing new licensing requirements for pharmaceutical import establishments. This decree modernizes the application process and strengthens oversight of pharmaceutical import activities, replacing the previous decree from December 2021. Authorized import establishments are required to align with the new requirements within 12 months of the decree's publication in the Official Journal.

TransData Nexus Research · Algeria regulatory databasesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Sarl Cpcm identified across shipments using consignee name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Sarl Cpcm's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 8 individual customs records matching Sarl Cpcm.
5.Supplier Verification: Sarl Cpcm sources from 2 verified Indian suppliers across 7 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

2 Products Tracked

1 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Sarl Cpcm

Sarl Cpcm — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Sarl Cpcm?

What Formulations Does Sarl Cpcm Import?

What Products Does Sarl Cpcm Import?

Top Products by Import Value

Sarl Cpcm Therapeutic Categories — 1 Specializations

Import Portfolio — Top 2 by Import Value

Key Metrics

Top Categories

Indian Suppliers

Sarl Cpcm — Corporate Profile & Information

1Company Overview

2Distribution Network

3Industry Role

Related Trade Data

Need Detailed Data?

Supplier Relationship Intelligence — Sarl Cpcm

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into Algeria — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Sarl Cpcm — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to Sarl Cpcm

1Opportunity Assessment

2Requirements & Qualifications

3How to Approach

Frequently Asked Questions — Sarl Cpcm

What products does Sarl Cpcm import from India?

Who supplies pharmaceuticals to Sarl Cpcm from India?

What is Sarl Cpcm's total pharmaceutical import value?

What therapeutic categories does Sarl Cpcm focus on?

Get Full Sarl Cpcm Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology